Products Liability Insurance for Pharmaceutical and Medical Device Contract Manufacturers: A Buyer's Guide

The short answer first

For a Texas pharmaceutical or medical device contract manufacturer with $10M to $50M in revenue, total program premium for a properly built products liability tower runs roughly $35,000 to $120,000 per year. The drivers, in order of impact:

1. Sales volume and product class (oral solid dose vs. injectable vs. biologics vs. controlled substance)
2. Whether the program is placed with a life-sciences-dedicated carrier or a generalist
3. Limit selection ($5M vs. $10M vs. $25M tower)
4. Quality system maturity, FDA inspection history, and recall history
5. Sponsor mix (number of distinct sponsors, their risk profile, MSA aggressiveness)

A surprising amount of variation between similar-looking accounts comes from item 2. The same $20M oral solid dose CDMO placed with a dedicated life-sciences market versus a generalist middle-market manufacturers carrier will often see a 20-40% premium difference for materially different coverage.

What products liability actually covers, for a contract manufacturer

Products liability for a CDMO is not the same as products liability for a widget manufacturer. The exposure architecture is different in three ways:

First, the loss event is usually patient harm, not property damage. A defective bracket in industrial equipment causes a downstream property loss. A defective tablet causes a hospitalization or a death. The severity distribution is much heavier in the tail.

Second, claims often arrive years after manufacture. Pharmaceutical and device claims have long tails — sometimes 5, 10, even 20 years between manufacture and claim filing. This is why occurrence-form coverage matters: an occurrence policy responds based on when the incident happened, not when the claim was reported.

Third, the recall is often as expensive as the liability claim. Pulling a batch of product back from market involves notification costs, transport, destruction, regulatory reporting, and lost revenue. A standalone product recall coverage extension or policy is increasingly required by sponsors.

The base CGL form provides products and completed operations coverage by default, but the form is generic. A contract manufacturer with $30M of pharmaceutical revenue should not be on the same form as a roofing contractor.

How the premium is actually calculated

For a life-sciences-class carrier, the rating logic typically looks like this:

| Factor | How it enters the rate | |---|---| | Sales volume | Base rate per $1,000 of sales, varying by product class | | Product class | Multiplier — oral solid dose lowest, injectable mid, biologics/cell-and-gene highest | | Limit | Increased Limit Factor (ILF) curve — diminishing cost per million as you add layers | | Quality system maturity | Underwriter discretion — strong cGMP, strong inspection history = credit | | Sponsor concentration | Higher concentration in one or two sponsors = surcharge | | Geography | Texas is generally favorable; California less so for tort exposure | | Loss history | Five years of loss runs reviewed; clean history = credit |

For a $20M oral solid dose CDMO with no losses, a $5M products tower might rate something like:

• $1M primary CGL with products: $18,000-$28,000
• $4M umbrella sitting over CGL/Auto/WC: $8,000-$15,000
• Subtotal products tower: $26,000-$43,000

Add property, cargo, cyber, and miscellaneous coverages and total premium often lands $50,000-$80,000.

For an injectable or sterile product manufacturer at the same revenue, the same tower might run $65,000-$140,000 — the difference is almost entirely the product class multiplier.

How to think about limit selection

Most sponsor MSAs require $5M for products and completed operations. Some require $10M. A few require $25M or more, particularly for oncology, biologics, or cell and gene therapy work.

There are three reasons to carry more than the highest single MSA requires:

1. Aggregate exhaustion across sponsors. If you have 10 sponsors all requiring $5M aggregate, and your aggregate is shared, a single bad year against one sponsor exhausts the limit available to the other nine. A per-project endorsement on the primary plus a robust umbrella mitigates this.

2. Tail liability survives the contract. Most occurrence policies respond based on when the incident happened, but if your business changes (you sell, you pivot, you wind down), keeping coverage in place for the statute of repose period can be a meaningful expense. A higher current limit reduces some of that tail risk by giving you more margin to absorb a late-emerging claim.

3. Indemnity exposure to the sponsor. Even with an indemnity cap aligned to insurance, the cap is your insurance limit. If your insurance is $5M and the sponsor's claim is $8M, the $3M gap is your balance sheet's problem. Pricing a $10M tower vs. a $5M tower for a manufacturer with $30M in equity is often the right answer.

The marginal cost of going from $5M to $10M is usually $10K-$30K depending on revenue and product class. From $10M to $25M is another step but the per-million cost is lower because of the diminishing ILF curve. Past $25M, you're typically into a wholesale-placed excess layer with London-market or Bermuda-market participation, and the economics get less attractive per dollar of cover.

The four endorsements that matter most

Beyond the base form, four endorsements drive most of the actual coverage quality on a CDMO program:

1. Additional insured for products and completed operations (CG 20 37 or equivalent)

The most common compliance gap. We covered the mechanics in the MSA insurance requirements guide. Briefly: a generic blanket AI endorsement (CG 20 33) typically excludes products / completed ops from AI status. For a contract manufacturer, that exclusion eliminates the entire point of the endorsement. CG 20 37 specifically extends AI status to the products and completed operations hazard.

2. Per-project or per-location aggregate (CG 25 03 / CG 25 04)

Without this, your $2M general aggregate is shared across every sponsor relationship. With this, it resets per project or per location, which is the structure your MSAs actually need.

3. Recall expense extension (or standalone recall policy)

A small-limit recall expense extension on the CGL ($25K-$250K) is cheap and covers basic logistics of pulling product. A standalone product recall and contamination policy ($1M-$10M) is more expensive but covers business interruption, rehabilitation, and broader third-party recall costs. For finished-product CDMOs, the standalone policy is usually worth pricing.

4. Drug master file / IP confidentiality endorsement

Less common but increasingly requested by sponsors with proprietary formulations. Confirms that your cyber and crime coverage extends to sponsor-confidential data and that your CGL does not exclude advertising injury claims arising out of unintentional disclosure of sponsor IP.

A program with all four endorsements properly written — even at modest base limits — is a meaningfully stronger placement than a generic manufacturer's program at twice the limits.

What markets underwrite this segment

Three or four dedicated life-sciences specialty insurers do most of the work in the U.S. middle-market segment, with characteristic profiles:

The pharma-and-biologics specialist. Will write injectable, biologic, and controlled-substance work where many carriers will not. Limit capacity is high (capable of $25M on a single tower for the right account). Underwriting is rigorous; expect a detailed application and likely an underwriter call.

The device and emerging-tech specialist. Strong on medical device contract manufacturing and on emerging-tech life sciences (digital health, diagnostics, cell and gene services). Comfortable with claims-made E&O alongside occurrence-form products.

The small-to-lower-middle-market specialist. Writes pharma and device CDMOs in the $5M-$30M revenue range with quoting often faster than the larger carriers. Capacity typically tops out around $5M-$10M on most placements; needs an excess partner above that.

For specialty exposures — large recall limits, very high products towers, controlled substance exposure beyond standard appetite, pre-revenue device companies — wholesale brokers route placements to Bermuda and London markets through specialty MGAs.

If your current placement is with a generalist middle-market manufacturers carrier on a non-life-sciences package, you should at minimum get a quote from a dedicated life-sciences market for comparison. The coverage quality difference is usually meaningful.

Common mistakes we see

Over-relying on the umbrella. Many CDMOs have $1M primary + $9M umbrella to satisfy a $10M sponsor requirement, and assume that means $10M of products coverage. It often doesn't — the umbrella may exclude products entirely above the primary, may have a separate (lower) products aggregate, or may have a narrower trigger than the primary.

Treating cyber as separate from products. A cyber event that compromises drug master file data or alters a manufacturing parameter that causes an out-of-spec batch is, in many policy forms, ambiguous between products liability and cyber. Coordinated coverage between the two policies, written by carriers who play together, matters.

Ignoring the products and completed ops aggregate. The general aggregate gets attention. The products and completed ops aggregate is its own separate limit on the same policy and is often the more important number for a contract manufacturer. Verify the products aggregate is at least equal to the per-occurrence limit.

Buying claims-made products coverage. Some specialty markets write products on a claims-made basis, which is dangerous for a contract manufacturer because of the long tail. If you ever stop renewing, you need to buy an Extended Reporting Period (ERP) tail, which is expensive — often 100-300% of the last full annual premium for unlimited tail. Occurrence form is the default for a reason.

A short framework for evaluating your current program

1. What is my products and completed ops per-occurrence limit? Should match the highest single MSA requirement, with a buffer.
2. What is my products and completed ops aggregate? Should equal or exceed per-occurrence.
3. Is products / completed ops aggregate separate from general aggregate? Yes is the right answer.
4. Does my umbrella explicitly schedule products / completed ops as covered underlying? Verify in writing.
5. Is my AI endorsement extending to products / completed ops? CG 20 37 or equivalent — this is the most common gap.
6. Is recall coverage included or by endorsement? Limit should match your batch value.
7. Is the carrier rated A- VII or better and life-sciences-class? If not, consider remarketing.
8. Has the program been re-underwritten in the last 24 months? Pharma sponsor MSA requirements have tightened materially since 2023.

If you cannot answer all eight from your current program documentation, that is the answer to whether the program needs review.

Related glossary entries: Products & Completed Operations $5M · Products & Completed Operations $10M · Umbrella $5M · Additional Insured — Products & Completed Ops · Recall Coverage